Transactions
28
Insider / BOSTON SCIENTIFIC CORP
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology at BOSTON SCIENTIFIC CORP
- Company
- BOSTON SCIENTIFIC CORP
- Ticker
- BSX
- First filing on record
- October 1, 2025
- Latest trade on record
- July 31, 2026
- SEC filings
- EDGAR ↗
Fitzgerald Joseph Michael, EVP & Group Pres, Cardiology at BOSTON SCIENTIFIC CORP, has disclosed 28 transactions in BSX since October 1, 2025: 0 purchases (0 open-market buys) and 9 sales, worth about $18.4M at the reported prices. The latest was filed August 3, 2026, 3 days after the trade; 10 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
9
Avg. disclosure lag
2.8d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Fitzgerald Joseph Michael made no purchases and 7 sales worth $7.9M, plus 17 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Fitzgerald Joseph Michael has traded 1 stock on record; the largest by dollars is BSX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
2 of 6 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 12 | 229,162 | $2.6M |
| S | Open-market sale | 5 | 100,000 | $9.9M |
| A | Grant or award | 4 | 132,122 | — |
| F | Shares withheld for tax | 4 | 38,512 | $2.9M |
| G | Gift | 2 | 10,300 | — |
| I | Discretionary transaction | 1 | 64,198 | $3.0M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 17 | 0 | 4 · $2.9M |
| 2025 | 11 | 0 | 5 · $9.9M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| BSX | Other I | July 31, 2026 | August 3, 2026 | 3d | 64,198 | $47 | $3.0M | indirect | Form 4 ↗ | |
| BSX | Option / conversion M | February 16, 2026 | February 18, 2026 | 2d | 3,960 | — | — | derivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 14, 2026 | February 18, 2026 | 4d | 4,362 | — | — | derivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 13, 2026 | February 18, 2026 | 5d | 2,797 | — | — | latederivative | Form 4 ↗ | |
| BSX | Sell F | February 16, 2026 | February 18, 2026 | 2d | 1,806 | $75 | $135K | Form 4 ↗ | ||
| BSX | Option / conversion M | February 16, 2026 | February 18, 2026 | 2d | 3,960 | — | — | Form 4 ↗ | ||
| BSX | Sell F | February 14, 2026 | February 18, 2026 | 4d | 1,990 | $75 | $149K | Form 4 ↗ | ||
| BSX | Option / conversion M | February 14, 2026 | February 18, 2026 | 4d | 4,362 | — | — | Form 4 ↗ | ||
| BSX | Sell F | February 13, 2026 | February 18, 2026 | 5d | 33,104 | $75 | $2.5M | late | Form 4 ↗ | |
| BSX | Option / conversion M | February 13, 2026 | February 18, 2026 | 5d | 2,797 | — | — | late | Form 4 ↗ | |
| BSX | Other A | February 13, 2026 | February 18, 2026 | 5d | 34,898 | — | — | late | Form 4 ↗ | |
| BSX | Other A | February 13, 2026 | February 18, 2026 | 5d | 34,898 | — | — | late | Form 4 ↗ | |
| BSX | Other A | February 12, 2026 | February 17, 2026 | 5d | 43,776 | — | — | latederivative | Form 4 ↗ | |
| BSX | Other A | February 12, 2026 | February 17, 2026 | 5d | 18,550 | — | — | latederivative | Form 4 ↗ | |
| BSX | Option / conversion M | February 12, 2026 | February 17, 2026 | 5d | 3,462 | — | — | latederivative | Form 4 ↗ | |
| BSX | Sell F | February 12, 2026 | February 17, 2026 | 5d | 1,612 | $74 | $119K | late | Form 4 ↗ | |
| BSX | Option / conversion M | February 12, 2026 | February 17, 2026 | 5d | 3,462 | — | — | late | Form 4 ↗ | |
| BSX | Other G | November 14, 2025 | November 14, 2025 | 0d | 9,610 | — | — | Form 4 ↗ | ||
| BSX | Other G | November 12, 2025 | November 14, 2025 | 2d | 690 | — | — | Form 4 ↗ | ||
| BSX | Option / conversion M | November 3, 2025 | November 4, 2025 | 1d | 50,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| BSX | Sell S | November 3, 2025 | November 4, 2025 | 1d | 29,472 | $99 | $2.9M | 10b5-1 plan | Form 4 ↗ | |
| BSX | Sell S | November 3, 2025 | November 4, 2025 | 1d | 16,928 | $100 | $1.7M | 10b5-1 plan | Form 4 ↗ | |
| BSX | Sell S | November 3, 2025 | November 4, 2025 | 1d | 3,600 | $101 | $363K | 10b5-1 plan | Form 4 ↗ | |
| BSX | Option / conversion M | November 3, 2025 | November 4, 2025 | 1d | 50,000 | $26 | $1.3M | 10b5-1 plan | Form 4 ↗ | |
| BSX | Option / conversion M | October 1, 2025 | October 1, 2025 | 0d | 50,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| BSX | Sell S | October 1, 2025 | October 1, 2025 | 0d | 41,755 | $98 | $4.1M | 10b5-1 plan | Form 4 ↗ | |
| BSX | Sell S | October 1, 2025 | October 1, 2025 | 0d | 8,245 | $99 | $815K | 10b5-1 plan | Form 4 ↗ | |
| BSX | Option / conversion M | October 1, 2025 | October 1, 2025 | 0d | 50,000 | $26 | $1.3M | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 3, 2026 | Form 4 | 0001225208-26-006881 | 1 | published | EDGAR ↗ |
| February 18, 2026 | Form 4 | 0001225208-26-002134 | 11 | published | EDGAR ↗ |
| February 17, 2026 | Form 4 | 0001225208-26-002015 | 5 | published | EDGAR ↗ |
| November 14, 2025 | Form 4 | 0001225208-25-009225 | 2 | published | EDGAR ↗ |
| November 4, 2025 | Form 4 | 0001225208-25-008911 | 5 | published | EDGAR ↗ |
| October 1, 2025 | Form 4 | 0001225208-25-008180 | 4 | published | EDGAR ↗ |
Other insiders at BOSTON SCIENTIFIC CORP
- Mahoney Michael F Chairman, President & CEO 30 rows
- Butcher Arthur C EVP& Grp Pres, MedSurg & APAC 29 rows
- O'Connor Padraig Andrew EVP, Global Operations 20 rows
- Monson Jonathan EVP and CFO 18 rows
- Woodworth Emily SVP, Global Controller and CAO 18 rows
- Brown Vance R EVP, GC and Corp. Secretary 16 rows
- O'Sullivan Miriam SVP, Chief HR Officer 15 rows
- Zane Ellen M Director 14 rows
- Smith Cathy R Director 11 rows
- Habiger David C Director 6 rows
Everyone on file, with contracts and lobbying under the company's name: BOSTON SCIENTIFIC CORP.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 6 | 28 | October 1, 2025 | August 3, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.